KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Khiron Life Sciences Corp. has received the National Interest Strategic Project certification (PINES) from the Colombian government, facilitating accelerated market entry for its cannabis products. This certification allows Khiron to expedite administrative processes and aims to register over 4 SKUs in medical cannabis and at least 10 in consumer packaged goods for domestic and export markets. Khiron is one of three companies to achieve this status, emphasizing the government's commitment to the medical cannabis sector and Khiron's business strategy.

Khiron Life Sciences Corp. announced the shareholder approval of its amended stock option and restricted share unit plans during the AGM on September 10, 2020. The Company can issue up to 13,398,580 shares under these plans, aimed at attracting and retaining key personnel. Following approval, the board granted 1,210,000 RSUs to directors and officers, vesting over three years. Khiron operates in Latin America and Europe, focusing on medical cannabis cultivation and distribution, and is committed to regulatory compliance and patient care.

Khiron Life Sciences Corp. will present at VirtualInvestorConferences.com on September 10, 2020, at 4:30 p.m. ET. CEO Alvaro Torres and Chairman Chris Naprawa will discuss the company’s advancements, including over 1,500 medical cannabis prescriptions issued since receiving authorization in Colombia. Khiron has expanded operations in the UK and Germany, launched a teleconsultation platform, and signed distribution agreements in the Hong Kong market. The event allows real-time questions and will be archived for later viewing.

Khiron Life Sciences Corp. announced its participation in a live presentation at VirtualInvestorConferences.com on September 10, 2020, at 4:30 p.m. ET. CEO Alvaro Torres and Chairman Chris Naprawa will engage directly with investors. Khiron, a leader in the cannabis sector with operations in Latin America and Europe, recently achieved significant milestones, including over 1,500 medical cannabis prescriptions in Colombia and expansion into the UK and Germany. For registration, visit here.

Khiron Life Sciences Corp. announced the granting of 1,140,000 restricted share units (RSUs) to certain directors and officers under its Amended and Restated RSU Plan. The grant includes 600,000 RSUs vesting in thirds over three years and 500,000 RSUs tied to performance milestones. Additional RSUs are also granted with various vesting conditions. This move highlights Khiron's commitment to align executive interests with shareholder value and enhance motivation within its leadership as it continues its operations in Latin America and Europe.

Khiron Life Sciences Corp. has partnered with the Medical Cannabis Clinicians Society (MCCS) to provide medical cannabis education to UK doctors starting Q3 2020. This initiative enhances Khiron's cloud-based learning platform, already active in Latin America. The program aims to equip doctors with knowledge about prescribing cannabis for conditions like chronic pain and anxiety, amidst a growing UK market projected to be worth nearly £1bn by 2024. This partnership addresses the critical need for education in the UK's medical cannabis landscape.

Khiron Life Sciences Corp. reported its Q2 2020 financial results amid COVID-19, achieving first high-THC cannabis sales in Colombia. The company recorded revenues of $1.67 million, down from $2.21 million in Q2 2019. A net loss of $5.71 million marked an improvement from $9.52 million the previous year. Despite challenges, Khiron exceeded 1,500 medical cannabis patient prescriptions in Colombia and launched a teleconsultation platform. The company ended Q2 with $20 million in cash, focusing on higher margin medical businesses.